Embecta (EMBC) Competitors

Embecta (NASDAQ:EMBC) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

Do analysts prefer EMBC or LIVN?

Embecta presently has a consensus price target of $19.00, indicating a potential upside of 30.01%. LivaNova has a consensus price target of $59.71, indicating a potential upside of 7.17%. Given Embecta's higher possible upside, equities analysts clearly believe Embecta is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
LivaNova	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00

Is EMBC or LIVN more profitable?

Embecta has a net margin of 7.58% compared to LivaNova's net margin of -16.13%. LivaNova's return on equity of 14.57% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Embecta	7.58%	-23.40%	14.46%
LivaNova	-16.13%	14.57%	6.91%

Which has better valuation & earnings, EMBC or LIVN?

Embecta has higher earnings, but lower revenue than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.12B	0.76	$78.30M	$1.43	10.22
LivaNova	$1.25B	2.43	$63.23M	-$3.89	-14.32

Which has more volatility and risk, EMBC or LIVN?

Embecta has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500.

Does the media prefer EMBC or LIVN?

In the previous week, LivaNova had 2 more articles in the media than Embecta. MarketBeat recorded 9 mentions for LivaNova and 7 mentions for Embecta. LivaNova's average media sentiment score of 1.53 beat Embecta's score of 1.27 indicating that LivaNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Embecta	4 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LivaNova	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Do insiders and institutionals believe in EMBC or LIVN?

93.8% of Embecta shares are owned by institutional investors. Comparatively, 97.6% of LivaNova shares are owned by institutional investors. 0.4% of Embecta shares are owned by company insiders. Comparatively, 0.3% of LivaNova shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

LivaNova beats Embecta on 9 of the 17 factors compared between the two stocks.